236 related articles for article (PubMed ID: 22628078)
1. Farnesyl pyrophosphate is an endogenous antagonist to ADP-stimulated P2Y₁₂ receptor-mediated platelet aggregation.
Högberg C; Gidlöf O; Deflorian F; Jacobson KA; Abdelrahman A; Müller CE; Olde B; Erlinge D
Thromb Haemost; 2012 Jul; 108(1):119-32. PubMed ID: 22628078
[TBL] [Abstract][Full Text] [Related]
2. Ticagrelor Inhibits Toll-Like and Protease-Activated Receptor Mediated Platelet Activation in Acute Coronary Syndromes.
Wadowski PP; Weikert C; Pultar J; Lee S; Eichelberger B; Koppensteiner R; Lang IM; Panzer S; Gremmel T
Cardiovasc Drugs Ther; 2020 Feb; 34(1):53-63. PubMed ID: 32062795
[TBL] [Abstract][Full Text] [Related]
3. Adenosine derived from ADP can contribute to inhibition of platelet aggregation in the presence of a P2Y12 antagonist.
Iyú D; Glenn JR; White AE; Fox SC; Heptinstall S
Arterioscler Thromb Vasc Biol; 2011 Feb; 31(2):416-22. PubMed ID: 21106949
[TBL] [Abstract][Full Text] [Related]
4. Competitive mode and site of interaction of ticagrelor at the human platelet P2Y12 -receptor.
Hoffmann K; Lutz DA; Straßburger J; Baqi Y; Müller CE; von Kügelgen I
J Thromb Haemost; 2014 Nov; 12(11):1898-905. PubMed ID: 25186974
[TBL] [Abstract][Full Text] [Related]
5. Blockade of the purinergic P2Y12 receptor greatly increases the platelet inhibitory actions of nitric oxide.
Kirkby NS; Lundberg MH; Chan MV; Vojnovic I; Solomon AB; Emerson M; Mitchell JA; Warner TD
Proc Natl Acad Sci U S A; 2013 Sep; 110(39):15782-7. PubMed ID: 24003163
[TBL] [Abstract][Full Text] [Related]
6. Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor.
Gerrits AJ; Jakubowski JA; Sugidachi A; Michelson AD; Frelinger AL
J Thromb Haemost; 2017 May; 15(5):858-867. PubMed ID: 28092426
[TBL] [Abstract][Full Text] [Related]
7. Prostaglandin E1 potentiates the effects of P2Y12 blockade on ADP-mediated platelet aggregation in vitro: Insights using short thromboelastography.
Khanna V; Armstrong PC; Warner TD; Curzen N
Platelets; 2015; 26(7):689-92. PubMed ID: 25734957
[TBL] [Abstract][Full Text] [Related]
8. P2Y12 antagonist ticagrelor inhibits the release of procoagulant extracellular vesicles from activated platelets.
Gasecka A; Nieuwland R; van der Pol E; Hajji N; Ćwiek A; Pluta K; Konwerski M; Filipiak KJ
Cardiol J; 2019; 26(6):782-789. PubMed ID: 29671861
[TBL] [Abstract][Full Text] [Related]
9. Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation.
VAN Giezen JJ; Nilsson L; Berntsson P; Wissing BM; Giordanetto F; Tomlinson W; Greasley PJ
J Thromb Haemost; 2009 Sep; 7(9):1556-65. PubMed ID: 19552634
[TBL] [Abstract][Full Text] [Related]
10. P2Y₁₂ and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP.
Iyú D; Glenn JR; White AE; Fox SC; Dovlatova N; Heptinstall S
Platelets; 2011; 22(7):504-15. PubMed ID: 21591981
[TBL] [Abstract][Full Text] [Related]
11. A clopidogrel-insensitive inducible pool of P2Y12 receptors contributes to thrombus formation: inhibition by elinogrel, a direct-acting, reversible P2Y12 antagonist.
Haberstock-Debic H; Andre P; Mills S; Phillips DR; Conley PB
J Pharmacol Exp Ther; 2011 Oct; 339(1):54-61. PubMed ID: 21730013
[TBL] [Abstract][Full Text] [Related]
12. SAR216471, an alternative to the use of currently available P2Y₁₂ receptor inhibitors?
Delesque-Touchard N; Pflieger AM; Bonnet-Lignon S; Millet L; Salel V; Boldron C; Lassalle G; Herbert JM; Savi P; Bono F
Thromb Res; 2014 Sep; 134(3):693-703. PubMed ID: 25064036
[TBL] [Abstract][Full Text] [Related]
13. The role of adenosine diphosphate mediated platelet responsiveness for the stability of platelet integrity in citrated whole blood under ex vivo conditions.
Koessler J; Schwarz M; Weber K; Etzel J; Koessler A; Boeck M; Kobsar A
PLoS One; 2017; 12(11):e0188193. PubMed ID: 29155852
[TBL] [Abstract][Full Text] [Related]
14. Adenosine diphosphate (ADP)-induced thromboxane A(2) generation in human platelets requires coordinated signaling through integrin alpha(IIb)beta(3) and ADP receptors.
Jin J; Quinton TM; Zhang J; Rittenhouse SE; Kunapuli SP
Blood; 2002 Jan; 99(1):193-8. PubMed ID: 11756171
[TBL] [Abstract][Full Text] [Related]
15. Nucleoside triphosphates inhibit ADP, collagen, and epinephrine-induced platelet aggregation: role of P2Y₁ and P2Y₁₂ receptors.
Aslam M; Sedding D; Koshty A; Santoso S; Schulz R; Hamm C; Gündüz D
Thromb Res; 2013 Nov; 132(5):548-57. PubMed ID: 24071464
[TBL] [Abstract][Full Text] [Related]
16. The effect of P2Y12 inhibition on platelet activation assessed with aggregation- and flow cytometry-based assays.
Leunissen TC; Wisman PP; van Holten TC; de Groot PG; Korporaal SJ; Koekman AC; Moll FL; Teraa M; Verhaar MC; de Borst GJ; Urbanus RT; Roest M
Platelets; 2017 Sep; 28(6):567-575. PubMed ID: 27885904
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic interplay of the P2Y(1), P2Y(12), and TxA(2) pathways in platelets: the potential of triple antiplatelet therapy with P2Y(1) receptor antagonism.
Oestreich JH; Ferraris SP; Steinhubl SR; Akers WS
Thromb Res; 2013 Feb; 131(2):e64-70. PubMed ID: 23245937
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory Effect of Flavonolignans on the P2Y12 Pathway in Blood Platelets.
Bijak M; Szelenberger R; Dziedzic A; Saluk-Bijak J
Molecules; 2018 Feb; 23(2):. PubMed ID: 29439388
[TBL] [Abstract][Full Text] [Related]
19. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
[TBL] [Abstract][Full Text] [Related]
20. Platelet P2Y₁₂ receptors are involved in the haemostatic effect of notoginsenoside Ft1, a saponin isolated from Panax notoginseng.
Gao B; Huang L; Liu H; Wu H; Zhang E; Yang L; Wu X; Wang Z
Br J Pharmacol; 2014 Jan; 171(1):214-23. PubMed ID: 24117220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
